<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37536051</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8421</ISSN><JournalIssue CitedMedium="Internet"><Volume>382</Volume><PubDate><Year>2023</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroimmunology</Title><ISOAbbreviation>J Neuroimmunol</ISOAbbreviation></Journal><ArticleTitle>Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.</ArticleTitle><Pagination><StartPage>578166</StartPage><MedlinePgn>578166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2023.578166</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-5728(23)00152-2</ELocationID><Abstract><AbstractText>Shikonin is an anti-inflammatory natural herbal drug extracted from Lithospermum erythrorhizon and its therapeutic effect on neuropsychiatric systemic lupus erythematosus (NPSLE) is yet unknown. In our study, Shikonin significantly reversed the cognitive impairment and alleviated the brain tissue damage in NPSLE mice. The permeability of blood-brain barrier was also verified to be repaired in Shikonin-treated NPSLE mice. In particular, we found that Shikonin alleviated neuroinflammation through inhibiting &#x3b2;-catenin signaling pathway, thereby depressing the activation of microglia and the loss of neuronal synapses. Overall, Shikonin may be a promising candidate drug for NPSLE through diminishing neuroinflammation and repairing neuron damage.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Jiali</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing 210093, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing 210093, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ruowen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing 210093, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hailin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing 210093, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yayi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing 210093, PR China. Electronic address: yayihou@nju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dou</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing 210093, PR China. Electronic address: douhuan@nju.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuroimmunol</MedlineTA><NlmUniqueID>8109498</NlmUniqueID><ISSNLinking>0165-5728</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3IK6592UBW</RegistryNumber><NameOfSubstance UI="C016101">shikonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Neuron</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Shikonin</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37536051</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2023.578166</ArticleId><ArticleId IdType="pii">S0165-5728(23)00152-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>